Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!
The goal of this study is to identify a safe dosing regimen for siplizumab in participants with type 1 diabetes. Siplizumab is a drug used to help treat recent onset type 1 diabetes mellitus (T1DM). This study is interested in participants aged 18-45 years with T1DM, who are within 18 months of receiving their diagnosis. Participants will be randomized (selected at random by the study team) to one of four possible treatment groups. All groups will receive weekly siplizumab doses administered subcutaneously (injected into the body through the skin) for a total of 12 weeks.
CHOP PriCARE is a FREE, VIRTUAL workshop for caregivers of children 18 months - 6 years of age. Caregivers attend the workshop for 80 minutes once a week for 6 weeks. Workshops are offered mornings and evenings throughout the year. The goal of the workshop is to teach ways to interact with young children that improve their behavior and build a strong bond between caregiver and child. The PriCARE workshop is a research project with two groups of caregivers. One group attends the workshop, and one group does not attend. Caregivers in both groups are very important for this project. All caregivers will be interviewed and get paid for their participation. To learn how you can participate, call 267-318-1707 or email pricare@chop.edu.
This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and NTRK fusion. The study involves taking a study drug called larotrectinib for approximately 6 months prior to receiving radioiodine therapy (RAI). The overall goal of this study is to find out if taking the study drug before RAI works better than receiving RAI alone (the usual standard of care treatment).
This prospective cohort study will compare breath biomarkers from subjects with mitochondrial disease to healthy controls. The age range for the study is 4-80 years and all subjects will be recruited at CHOP. Participation would consist of a one time visit, up to 2 hours maximum, to collect identifiable information and breath sample. The goal is to identify VOC biomarkers that characterize mitochondrial disease compared to healthy controls, which could lead to a non-invasive breath test for mitochondrial function. Subjects will be compensated as a form of appreciation for participating in the study.
This research study is being conducted to look at oxygen as a treatment of obstructive sleep apnea (OSA) in children with Down syndrome. The main reason for the study is to show how 6 months of oxygen treatment while sleeping affects the participants sleep, quality of life, breathing, heart and if it makes the participant feel better.
This study involves taking the study drug, abatacept, by intravenous (IV) infusion. Along with the study drug, participants will take a either cyclosporine or tacrolimus, and methotrexate, which are standard medications for transplant patients. Participants, 6 years of age and older, will be randomized (placed into a group by chance) by the study team. After being placed into a group, you will receive additional doses of either abatacept (the study drug) or a placebo (an inactive substance).
Are you interested learning about opportunities to participate in research? Sign up to receive information about new research studies at CHOP. It’s a great way to support the work of the Research Institute.